The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In another sizable deal for Denali Therapeutics, Sanofi is paying $125 million to buy into a series of neuroinflammation compounds called RIPK1 inhibitors. The pact provides key funding for the ...
In a recent study published in the journal Nature Cell Biology, researchers investigated how N-acetyltransferase (NAT)-mediated post-translational modification, acetylhypusination, regulates insulin ...
The IKK complex protects cells from death by inactivating RIPK1, thereby revealing an unexpected NF-kB-independent new role of the IKK complex, investigators have revealed. The team of Prof. Bertrand ...
On the afternoon of May 4, the online academic event Master Forum was successfully held, co-organized by the Clinical ...
Eli Lilly and Company will collaborate with Rigel Pharmaceuticals to develop a small-molecule inhibitor of RIPK1, a kinase involved in cell death and inflammation. Lilly will pay Rigel $125 million up ...
This new article publication from Acta Pharmaceutica Sinica B, discusses how the protein arginine methyltransferase PRMT1 ameliorates cerebral ischemia–reperfusion injury by suppressing RIPK1-mediated ...
Just two weeks after Sanofi laid out $125 million to take a stake in two RIPK1 inhibitors being developed by Denali, the two companies are advancing one of those drugs into clinical trials in three of ...
Scientists from Australia and the US have discovered and identified the genetic cause of a previously unknown human autoinflammatory disease. The researchers determined that the autoinflammatory ...
Receptor-interacting protein kinase 1 (RIPK1) regulates cell cycle and counteracts necroptosis, and is hence considered a target to watch in necroptosis-related conditions such as cancer or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results